FeesSafety
Pluang+

New Proof of Human feature links Alien ID to Solana wallets for real user verification.

Protocol Fundamentals
24 Oct 2026
Tokenpost
View Source
Neutral
New Proof of Human feature links Alien ID to Solana wallets for real user verification.

A new Proof of Human feature allows users to link an Alien ID to any Solana wallet, verifying that a real person controls the wallet. This initiative aims to enhance trust and security in blockchain transactions by confirming human identity behind wallet usage. Additionally, World ID has integrated human verification checks with four tech companies—Okta, Vercel, Exa, and Browserbase—to ensure AI services have real human approval or involvement. These developments highlight growing efforts to combine identity verification with blockchain and AI technologies.

Solana's new Proof of Human Wallet feature is the subject, with Pluang market data providing context as of Oct 24, 2026 20:01 WIB. For readers following major cryptocurrencies, 5 of 50 priced assets rose while 43 fell today. Notable movers include AXS at Rp17.405 with a 1-day change of -4.58% and 100% buy order activity, GRT at Rp415 down 4.46% with 72% buy orders, and LINK at Rp209.213 down 4.33% with 91% buy orders.

More News

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
2 hours ago
Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
2 hours ago
Perioperative apalutamide plus ADT cuts risk of prostate cancer recurrence or death by 62% versus surgery alone

Perioperative apalutamide plus ADT cuts risk of prostate cancer recurrence or death by 62% versus surgery alone

New Phase 3 PROTEUS substudy results show that adding apalutamide plus androgen deprivation therapy (ADT) before and after surgery reduces the risk of prostate cancer recurrence or death by 62% compared to surgery alone in high-risk localized or loca...

Market News
Bullish
4 hours ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
4 hours ago
Three ultra-high-yield BDC lenders offer 13%+ payouts, but only Blue Owl's dividend looks sustainable.

Three ultra-high-yield BDC lenders offer 13%+ payouts, but only Blue Owl's dividend looks sustainable.

Three business development companies (BDCs) offer yields above 13%, but their payout sustainability varies. FS KKR Capital yields 21.3% but shows red flags like negative earnings and a shrinking loan book, making its dividend risky. Blue Owl Capital ...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App